

OKLAHOMA BOARD OF NURSING
2915 North Classen Boulevard, Suite 524
Oklahoma City, OK 73106
(405) 962-1800

FORMULARY ADVISORY COUNCIL
Minutes – August 11, 2016

The Formulary Advisory Council to the Oklahoma Board of Nursing met on August 11, 2016. Written notice of the meeting was filed with the Secretary of State's Office on December 10, 2015. Notice was posted on the Oklahoma Board of Nursing web site. A notice agenda was also posted on the Cameron Building front entrance at 2915 North Classen Boulevard, Oklahoma City, Oklahoma, as well as the Board office, Suite 524, at 8:00 AM on August 8, 2016 and not less than 24 hours prior to the meeting.

Place of Meeting: Basement Conference Room, Cameron Building

Time of Meeting: 2:30 PM

Members Present:

Tim Anderson, DPh	Oklahoma Pharmacists Association
Mary Jane Fry, DPh	Oklahoma Pharmacists Association
L. Harkess, APRN, CNM, CNP	Oklahoma Board of Nursing
Meri Hix, DPh, BCPS, CGP	Oklahoma Pharmacists Association
Deborah Booton-Hiser, APRN, CNP, PhD	Oklahoma Board of Nursing
Robert Holsey, DO, DPh	Oklahoma State Osteopathic Assoc.
Jay Kinnard, DPh	Oklahoma Pharmacists Association
Edward Legako, MD	Oklahoma State Medical Association
Mandy Nelson, APRN, CNS	Oklahoma Board of Nursing
Robin Kimball-Potter, APRN, CNS	Oklahoma Board of Nursing
Dana Stone, MD	Oklahoma State Medical Association

Members Absent:

Harold Ginzburg, MD, JD, MPH	Oklahoma State Medical Association
------------------------------	------------------------------------

Guests:

N. Elliott	SWOSU Pharmacy Student
Reba Gillispie	SWOSU Pharmacy Student
Kristi Rice	Walgreens Pharmacy Resident

Board Staff Representative:

Jackye Ward, MS, RN
Gina Stafford, BSN, RN

1.0 Preliminary Activities

1.1 **Call to Order:** The meeting was called to order by Deborah Booton-Hiser, Chairperson, at 2:32 PM.

1.2 **Declaration of quorum:** A quorum was declared present.

2.0 **Council decision regarding approval of council meeting minutes for August 13, 2015:** It was moved (J. Kinnard) and seconded to approve the minutes of August 13, 2015.

Voting:

Yes: (11) T. Anderson, M. Fry, L. Harkess, D. Booton-Hiser, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, R. Kimball-Potter, D. Stone

No: (0)

Absent: (1) H. Ginzburg

Motion carried.

3.0 Verbal reports requiring no action by committee:

3.1 **Changes to the *Oklahoma Nursing Practice Act:*** J. Ward summarized changes related to the *Oklahoma Nursing Practice Act* which will become effective November 1, 2016.

3.2 **Review of revisions of the *Rules of the Board:*** J. Ward reported that the Governor had signed the declaration of approval/disapproval of this year's proposed permanent *Rules*. The Board of Nursing proposed permanent *Rules* which were adopted and submitted to the Governor and Legislature prior to April 1, 2016, were considered approved and finally adopted on June 9, 2016 and will become effective August 25, 2016. Ms. Ward reviewed the changes related to educational surveys of Oklahoma nursing programs performed by the Oklahoma Board of Nursing staff.

3.3 **Report on National Nurse Licensure Compact:** J. Ward reported that House Bill 2482 passed the legislative session. This allows for Oklahoma to join the New Enhanced Nurse Licensure Compact. Currently, 10 states have passed the required legislation. The New Enhanced Nurse Licensure Compact will be implemented the sooner of 26 states join or December 31, 2018.

3.4 Other: G. Stafford provided information on the Comprehensive Addiction and Recovery Act of 2016. The President signed S.524 on July 22, 2016. The Bill addresses the formation of a national task force, authorizing grant programs for education and prevention, expands prescribing of treatment to “Nurse Practitioners”. The Bill language does not use the title “Advanced Practice Registered Nurse”. Therefore, Clinical Nurse Specialists, Certified Nurse Midwives and Certified Registered Nurse Anesthetist are not addressed in the Bill.

4.0 Review the Request to Amend Exclusionary Formulary sent by Karen Ann Taylor, APRN-CNP, PMHNP-BC:

Discussion regarding removal of Clozapine from the Exclusionary Formulary: Concerns were expressed regarding the need for additional data. Council members expressed curiosity as to where in the state problems are being experienced specific to APRNs not being able to prescribe Clozapine. Discussion continued regarding the safety of the drug. Also, it was mentioned that the new registry, Risk Evaluation Mitigation Strategy Program (REMS), has only been in use for 9 months. The drug warnings and Risk Evaluation Mitigation Strategy Program (REMS) requirements were reviewed and discussed. It was moved (M. Fry) and seconded to deny Karen Ann Taylor’s request to amend the Exclusionary Formulary by removal of Clozapine at this time, but to send a survey to all Mental Health APRNs and collect data from the REMS registry to review in the next meeting.

Voting:

Yes: (7) M. Fry, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, D. Stone

No: (4) T. Anderson, L. Harkess, D. Booton-Hiser, R. Kimball-Potter,

Absent: (1) H. Ginzburg

Motion carried.

5.0 Review changes related to Clozaril (Clozapine) since the last meeting, August 13, 2015: Information regarding the new Risk Evaluation Mitigation Strategy Program (REMS) was provided during the discussion of the request to amend the *Exclusionary Formulary* by removing Clozaril (Clozapine). Changes to the new registry included the requirement to monitor ANC and not accept WBC and added prescribing flexibility to providers. It was noted that nationally, Advanced Practice Nurse Practitioners could apply to the registry if they want to order Clozaril (Clozapine). Also, *FDA Safety Drug Communication* and *Safety Labeling*

Changes Approved by the FDA related to Clozapine were reviewed prior to the Council's decision to not remove Clozapine from the Exclusionary Formulary. There was no motion or vote, only a review of information.

6.0 Review and recommendations to the Oklahoma Board of Nursing on the revisions to *Advanced Practice Nurses with Prescriptive Authority Exclusionary Formulary -#P-50B*:

- **Draft revisions proposed by staff:** G. Stafford reported the process for reviewing and revising the *Exclusionary Formulary*. Review included all new drugs assigned classification in the *2016 American Hospital Formulary Service Drug Information Book*.
- **Discussion regarding new drugs:** G. Stafford reviewed the list of new drugs. The council reviewed drug information regarding Aristada, Vraylar and Probuphine, all new drugs with a boxed warning. The council determined Aristada and Vraylar could be ordered by Advanced Practice Registered Nurses and did not need to be placed on the *Exclusionary Formulary*. The council placed Probuphine on the *Exclusionary Formulary*.
- **Other recommendations:** Droperidol was removed for the *Exclusionary Formulary*. It is no longer available.

It was moved (M. Fry) and seconded to move the *Exclusionary Formulary* with discussed revisions forward to the Board for approval

Voting:

Yes: (11) T. Anderson, M. Fry, L. Harkess, D. Booton-Hiser, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, R. Kimball-Potter, D. Stone

No: (0)

Absent: (1) H. Ginzburg

Motion carried.

7.0 Review and approval of the *Request to Amend the Formulary*: A motion was made (E. Legako) and seconded to send the *Request to Amend the Formulary* without changes to the Board for approval.

Voting:

Yes: (11) T. Anderson, M. Fry, L. Harkess, D. Booton-Hiser, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, R. Kimball-Potter, D. Stone

No: (0)

Absent: (1) H. Ginzburg

Motion carried.

8.0 Council decision regarding election of chairperson and vice-chairperson:

8.1 Motion made (Robin Kimball-Potter) and seconded that D. Booton-Hiser serve as Chairperson.

Voting:

Yes: (11) T. Anderson, M. Fry, L. Harkess, D. Booton-Hiser, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, R. Kimball-Potter, D. Stone

No: (0)

Absent: (1) H. Ginzburg

Motion carried.

8.2 Motion made (M. Fry) and seconded that J. Kinnard serve as Vice Chairman

Voting:

Yes: (11) T. Anderson, M. Fry, L. Harkess, D. Booton-Hiser, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, R. Kimball-Potter, D. Stone

No: (0)

Absent: (1) H. Ginzburg

Motion carried.

9.0 Date for next meeting: Motion made (Mary Jane Fry) and seconded for the next meeting date for the Formulary Advisory Council to be set for *Thursday, August 10, 2017, at 2:30 PM.*

Voting:

Yes: (11) T. Anderson, M. Fry, L. Harkess, D. Booton-Hiser, M. Hix, R. Holsey, J. Kinnard, E. Legako, M. Nelson, R. Kimball-Potter, D. Stone

No: (0)

Absent: (1) H. Ginzburg

Motion carried.

10.0 Adjournment: There being no further business, the meeting adjourned at 4:00 p.m.